SCHEMBL3013271

SCHEMBL3013271

Cc1cc(C)cc(-c2csc(N3CCC(S(=O)(=O)c4cccc(Cl)c4)CC3)n2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.52
SMN1; SMN2 Q16637 7/20 0.52
NPC1 O15118 6/20 0.45
MAPT P10636 5/20 0.43
KMT2A Q03164 2/20 0.43
CYP1A2 P05177 2/20 0.43
CYP2C9 P11712 2/20 0.43
CYP2C19 P33261 2/20 0.43
ALDH1A1 P00352 2/20 0.43
HTT P42858 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
POLB P06746 1/20 0.43
HPGD P15428 1/20 0.43
LMNA P02545 3/20 0.42
MAPK1 P28482 2/20 0.42
MEN1 O00255 1/20 0.42
KDM1A O60341 3/20 0.41
MAOA P21397 2/20 0.41
GAA P10253 1/20 0.41
KDM4E B2RXH2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3010126 0.93 SMN1; SMN2 (0.56) RAB9ASMN1; SMN2NPC1MAPTKMT2A
SCHEMBL3015000 0.92 SMN1; SMN2 (0.53) RAB9ASMN1; SMN2NPC1MAPTKMT2A
SCHEMBL2999993 0.92 RAB9A (0.59) RAB9ASMN1; SMN2NPC1MAPTKMT2A
SCHEMBL3018990 0.91 SMN1; SMN2 (0.45) RAB9ASMN1; SMN2NPC1MAPTKMT2A
SCHEMBL3020234 0.89 RAB9A (0.47) RAB9ASMN1; SMN2NPC1MAPTKMT2A
SCHEMBL3015016 0.89 RAB9A (0.58) RAB9ASMN1; SMN2NPC1MAPTKMT2A
SCHEMBL3015361 0.89 SMN1; SMN2 (0.47) RAB9ASMN1; SMN2NPC1MAPTKMT2A
SCHEMBL3015722 0.89 SMN1; SMN2 (0.55) RAB9ASMN1; SMN2NPC1MAPTKMT2A
SCHEMBL3013830 0.89 RAB9A (0.53) RAB9ASMN1; SMN2NPC1MAPTKMT2A
SCHEMBL3010949 0.88 RAB9A (0.45) RAB9ASMN1; SMN2NPC1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA RAB9A 2943/4885SMN1; SMN2 1/4885NPC1 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.